Dengue Vaccines

Dengue Vaccines

There is one approved dengue vaccine authorized by the U.S. Centers for Disease Control and Prevention (CDC) and in various countries around the world, with several dengue vaccine candidates in clinical studies.

Dengue Vaccines

  • Dengvaxia (CYD-TDV) is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes.
  • TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus, each of which can cause dengue fever or Severe Dengue.
  • DV1-DV4 vaccine candidate is now transitioning into the human clinical study. This new vaccine construct, which comprises Nature’s gene-chip peptides bound to a quantum cluster gold nanoparticle delivery system, was shown to have an excellent safety profile in a repeat dose Good Laboratory Practice grade toxicology study using a standard industry model.
  • TetraVax-DV-TV003 is a live attenuated recombinant tetravalent investigational dengue vaccine. The vaccine was developed by Dr. Stephen Whitehead’s laboratory at NIH’s National Institute of Allergy and Infectious Diseases.

Dengue Virus Antigen Detection

NS1 tests detect the non-structural protein NS1 of the dengue virus. This protein is secreted into the blood during dengue infection. NS1 tests have been developed for use in serum. Most of these tests use synthetically labeled antibodies to detect dengue NS1 protein, says the CDC.

Mayo Clinic: Dengue Virus: A Diagnostic Testing Update: January 6, 2020.

  • The Dengue NS1 DetectTM Rapid Test is an immunochromatographic strip assay for the qualitative presumptive detection of non-structural protein 1 (NS1) in human serum. This test serves as an aid in the clinical laboratory diagnosis of early Dengue infections even prior to the presence of IgM or IgG antibodies in patients with clinical symptoms consistent with Dengue infection. This test is intended to be used on sera drawn from patients within 1-7 days past the onset of symptoms.
  • UltaLabs Dengue tests.

Dengue Vaccine News

October 14, 2020 - The U.S. CDC issued a Level 1 Travel Alert for the Americas. Dengue is an ongoing risk in many parts of Central and South America, Mexico, and the Caribbean (map). Travelers to areas of risk should protect themselves by preventing mosquito bites.

September 22, 2020 - The Florida Department of Health in Miami-Dade County (DOH-Miami-Dade) is under a mosquito-borne illness alert. A case of dengue fever of local transmission has been confirmed in a Miami-Dade resident. There has been a total of two locally acquired dengue cases in 2020.

September 21, 2020 - The authors of a non-peer-reviewed study published hypothesized that a safe and effective dengue vaccine could offer some immunity against SARS-CoV-2.

August 27, 2020 - The World Mosquito Program (WMP) of Monash University and its Indonesian partners the Tahija Foundation and Universitas Gadjah Mada have announced the first results of a cluster randomized controlled trial of its Wolbachia method, showing a 77% reduction in the incidence of virologically-confirmed dengue in Wolbachia-treated areas of Yogyakarta, Indonesia, compared to untreated areas. 

August 7, 2020 - The regional health authorities of Occitanie reported an autochthonous dengue transmission in Cessenon-surOrb, in Hérault prefecture. This case was infected in mid-July. Response measures are being undertaken by the competent authorities and outbreak investigations have enabled the identification of the primary case in a returning traveler from a dengue risk zone. This is the first autochthonous transmission reported in continental France in 2020. Background: Autochthonous dengue cases have been reported in continental Europe in recent years. In 2019, ten cases were reported in France (9) and Spain (1). One additional sexual transmission of dengue was reported in Madrid, Spain, in 2019.

July 23, 2020 - The Florida Department of Health (DOH) recently issued a mosquito-borne illness alert following the detection of locally-acquired dengue fever cases in Monroe County, the jurisdiction that includes the Florida Keys in South Florida.

July 13, 2020 - Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study.

June 23, 2020 - A Phase 1, Open-Label- Assessment of a Dengue Virus-1 Live Virus Human Challenge - (DENV-1-LVHC) Strain.

May 21, 2020 - The ongoing Dengue risk in the Americas continues into the summer of 2020, says the US Centers for Disease Control and Prevention (CDC). The CDC announced many parts of Central and South America, Mexico, and the Caribbean have continued to report dengue fever cases.

March 17, 2020 - Results published in the first paper from an 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall efficacy and safety data reported in the previously published 12-month analysis.

February 26, 2020 - The Chile Ministry of Health informed the WHO of confirmed cases of autochthonous dengue fever reported on Easter Island. These 3 cases are middle-age females, with no recent travel history.

November 6, 2019 - New England Journal of Medicine publishes primary endpoint analysis from an ongoing Phase 3 study of Takeda’s dengue vaccine candidate.

July 15, 2019 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain.

January 26, 2019 - This mosquito-borne disease, known as 'breakbone fever' due to its sometimes painful symptoms, infects many U.S. travelers.

November 14, 2018 - Preliminary data regarding a live-attenuated tetravalent dengue vaccine candidate developed by Takeda show that the vaccine may be able to protect against all four serotypes of the infection, according to research presented at the annual meeting of the American Society of Tropical Medicine and Hygiene.

March 16, 2016 - Experimental dengue vaccine protects all recipients in a virus challenge study.

Dengue Overview

Dengue is a mosquito-borne viral infection that is common in warm, tropical climates. Infection is caused by any one of four closely related dengue viruses (called serotypes) and these can lead to a wide spectrum of symptoms, including some which are extremely mild to those that may require medical intervention and hospitalization.

The dengue virus complex is primarily comprised of four different dengue virus serotypes, which are roughly 65% genetically identical to each other and all members are transmitted by Aedes species mosquitos, specifically, Aedes aegypti and Aedes albopictus, says the Mayo Clinic. In Severe Dengue cases, fatalities can occur.

Note: The content on this webpage is aggregated from the WHO, the U.S. CDC, research studies, and various media sources. This content is reviewed for efficacy by healthcare providers, such as Dr. Bob Carlson.